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MarA/Rob/MarR
MarA is a member of the AraC family of transcriptional
regulators (6) and activates over a dozen genes comprising the
Escherichia coli mar (multiple antibiotic resistance) regulon (7,
8). MarA does not bind antibiotics as part of its transcription
regulation mechanism. This 129-residue protein binds as a
monomer to asymmetric 20-bp operators (1), which contrasts to
* This minireview will be reprinted in the 2002 Minireview Compendium, which will be available in December, 2002. This work was supported by National Institutes of Health Grant AI48593 (to R. G. B.) and
Training Grant GM08617-05 (to M. H. G.) and by grants from the
National Science Foundation and the N. L. Tartar Trust.
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The abbreviations used are: mdr, multidrug resistance; TPP⫹, tetraphenylphosphonium; BRC, BmrR C terminus; HTH, helix-turn-helix;
r.m.s., root mean square; R6G, rhodamine 6G.
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Multidrug resistance (mdr)1 can be defined broadly as the
ability of a cell to survive ordinarily lethal doses of more than
one drug. Clearly, such resistance is a critical problem in the
treatment of fungal and bacterial infections and cancer. Four
general, but nonexclusive, mechanisms give rise to multidrug
resistance: 1) detoxification by enzymatic modification or cleavage of drug; 2) genetic alteration of the intra- or extracellular
targets; 3) decreased permeability of the cell membrane; and 4)
active drug extrusion by multidrug transporters.
Paramount to our understanding of mdr is the issue of recognition of structurally dissimilar substrates and how drug
binding effects function. In bacteria many multidrug transporters are regulated directly (locally) by transcription factors,
which also bind the substrates of these transporters, i.e. the
drug can act as a transcriptional coactivator or inducer. Multiple
mdr transporter genes are also regulated globally by activators
such as MarA that do not necessarily bind drugs (1). The regulators are of keen interest because they are more amenable to
structural studies than the membrane-bound transporters and
thus offer a greater chance to obtain high resolution views of
multidrug binding. Moreover, the local gene regulators are
equally interesting as their DNA complexes directly reveal the
mechanism of mdr transporter gene regulation. This minireview
will summarize the structures of known bacterial mdr regulators. Because our focus is more structural the reader is referred
to one of several recent reviews that discuss the more biological
aspects of global and local mdr regulation (2–5).

most prokaryotic transcriptional regulators that are dimers
and bind palindromic or pseudopalindromic DNA (9 –11).
The structure of MarA bound to the marA operator reveals the
basis of its DNA binding mechanism (Fig. 1a) (12). The protein
consists of seven ␣ helices, six of which comprise two three-helix
bundles each containing a helix-turn-helix (HTH) motif. The
remaining “linker” helix connects the two HTH motifs, thus creating a monomer with two DNA-reading heads. The independent
HTH elements bind adjacent major grooves, and because the two
“recognition helices” have different amino acid sequences each
makes a distinct set of contacts to the DNA bases, thus explaining the ability of the MarA monomer to bind asymmetric operator
sequences. To gain such specificity otherwise would require heterodimerization, such as that displayed by the eukaryotic transcriptional regulators Myc-Max (13, 14), Fos-Jun (15), and AHRARNT (16), or a second DNA binding element, e.g. a wing (17, 18).
To bind a cognate DNA site, MarA must significantly bend
the DNA. Bending occurs because the recognition helices of
MarA are separated by only 27 Å, and the conformational
flexibility of the protein appears to be limited by the linker
helix. Thus, to accommodate the shorter distance and bind
consecutive major grooves, MarA “pulls” the major grooves
toward itself, causing two kinks in the DNA at each HTH
binding site and the narrowing of the minor groove. These
localized kinks result in a global DNA bend of ⬃35° (12).
The structure of a second AraC family member, E. coli Rob, has
also been solved bound to DNA (19). Rob, like MarA, can activate
the mar operon when overexpressed (20). However, unlike MarA,
Rob contains an additional ⬃200-residue C-terminal domain of
unknown function but which is structurally similar to the E. coli
galactose-1-phosphate uridyltransferase (21). Recent NMR studies on the activation of the rob regulon by 2,2⬘-dipyridyl have
shown that the C-terminal domain of Rob binds this activator
directly and that binding is necessary for up-regulation (22). As
expected, MarA and the N-terminal, DNA binding domain of
Rob, the sequences of which are 51% identical, are structurally
similar. An overlay of all the main chain atoms of their conserved
domains results in an r.m.s. deviation of 0.9 Å (19), yet their
modes of DNA binding are quite different (Fig. 1a). Only the
N-terminal HTH motif of Rob is inserted into the major groove.
The C-terminal HTH sits on the surface of the double helix and
makes a lone DNA contact from residue Arg-90 to the phosphate
backbone. This binding mode allows Rob to contact unbent DNA.
Interestingly, Rob can also bind bent DNA (23) but to do so in a
MarA-like fashion would require the relocation of a ␤ hairpin
(19). Understanding the mechanistic implications of the plasticity of the DNA binding mode(s) of this subclass of the AraC family
will require additional structures of Rob-DNA and perhaps
MarA-DNA complexes.
Whereas MarA, and perhaps Rob, responds to multidrug
intrusion, the former constitutive activator does not bind
drugs. Rather, its gene expression is negatively regulated by a
dimer of MarR (7), a multidrug binding repressor that acts on
the marRAB locus. MarR binds a variety of anionic lipophilic
compounds, such as salicylate, which inhibit its repression of
the marRAB operon (24). The structure of the 144-residue
MarR protein bound to salicylate has been determined and
reveals an ␣/␤ protein composed of 6 ␣ helices and 3 ␤ strands
(25). Overall, the dimer appears to have the shape of a highway
safety triangle (Fig. 1b). The dimer interface, which buries
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FIG. 1. The structures of MarA, Rob, and MarR. a, aligned structures of MarA (blue) and Rob (red) bound to their respective DNA sites.
MarA bends the DNA toward the protein such that both HTH motifs are
inserted into consecutive major grooves. In contrast, Rob shows one HTH
binding a major groove, while the other sits on the phosphate backbone of
the unbent DNA. b, dimer of MarR. One subunit is colored from blue (N
terminus) to red (C terminus). One recognition helix is green and located
at the bottom of the monomer in this view. Bound salicylates are shown as
ball and sticks.

BmrR/BRC/MtaN
BmrR (Bacterial multidrug resistance Regulator) is a MerR
family member (28) from Bacillus subtilis that, upon binding
one of its structurally unrelated lipophilic cationic ligands,
activates transcription of the multidrug transporter gene bmr by
reconfiguring the 19-bp spacer between the ⫺10 and ⫺35 promoter elements (29, 30). Many BmrR ligands (coactivators) are
also substrates of the multidrug transporter Bmr. Like most
MerR family members, BmrR contains three domains: an Nterminal DNA binding domain, a linker/dimerization region, and
a C-terminal coactivator binding domain. The C termini of MerR
family members are quite variable, which is consistent with their
functions to respond to a wide variety of cellular stresses.
To facilitate structural studies on BmrR, a 159-residue ligand
binding domain, designated BRC (for BmrR C terminus) was
crystallized (31), and the structures of its drug-free and tetraphenylphosphonium (TPP⫹) bound forms were determined (32). The
BRC䡠TPP⫹ structure unveiled an internal multidrug binding
pocket lined with multiple aromatic amino acids, which participate in van der Waals and stacking interactions with the four
phenyl rings of the TPP⫹ ligand. Importantly, the bottom of the
pocket features a glutamate residue, Glu-253, buried in the hydrophobic core of the protein. Glu-253 makes the key electrostatic
interaction with TPP⫹, which is enhanced by the low dielectric
constant of the protein interior (33). Interestingly, the binding
pocket cannot be detected in the drug-free structure as residue
Glu-253 is buried within the hydrophobic core where its carboxylate group is “neutralized” by hydrogen bonds to the hydroxyl
groups of three tyrosine residues. To allow ligand access to this
binding site, a short ␣-helical shield undergoes a helix-to-coil
transition and moves away from the protein. The interactions
between BRC and TPP⫹ suggest a similar binding mode for other

hydrophobic cationic ligands of BRC/BmrR, such as rhodamine
6G (R6G) (32). Clearly, because all BmrR ligands are lipophilic
cations, the electrostatic interaction between positively charged
ligands and the negatively charged glutamate is key to the cation
selectivity of BmrR. Indeed, the replacement of Glu-253 with the
isosteric but electroneutral amino acid glutamine diminishes
drug binding significantly but does not perturb the global structural integrity of the protein (32).2
The ligand selectivity of BRC depends not only on the presence of the negatively charged glutamate but also on the architecture and chemistry of the binding site. Although the structural flexibility of the binding site is unknown, the hydrophobic
side chains likely rotate to accommodate different drugs. Mutational analysis of the BRC residues directly participating in
TPP⫹ binding showed that each mutation affected the binding
affinity of a variety of ligands differently (34). This suggests
that although drugs bind in the same general location, each
forms a distinct set of stacking and van der Waals contacts with
the residues in the binding site. The structures of additional
BRC-drug complexes should clarify this issue.
The structures of full-length BmrR in complex with DNA and
a drug (35) and of MtaN (multidrug transporter activation, N
terminus), also from B. subtilis, have been solved (36) (Fig. 2).
BmrR is the first intact MerR family member to have its structure determined, and the structure of MtaN, a constitutive activator of transcription, is the first of a MerR family member solved
in the absence of DNA or coactivator. Drug binding by BmrR is
similar to that of the BRC in that residue Glu-253 is still involved
and aromatic residues line the pocket and stack with TPP⫹.
However, the BmrR structure also reveals the possible involvement of residue Asp-47⬘, which is located in the DNA binding
domain of the other subunit, and Glu-266. Site-directed mutagenesis of each of these acidic residues and drug binding studies are needed to elucidate their contribution to binding. Regardless, Glu-253 appears to be the electrostatic key to TPP⫹ binding
because the BRC, which is missing Asp-47⬘, binds this activator
2

J. L. Huffman, M. C. Miller, and R. G. Brennan, unpublished data.
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3,570 Å2 of accessible surface area, is formed mainly by the N
and C termini of the monomers. A winged helix DNA binding
motif is found in the middle of the protein sequence. In this
conformation, MarR cannot bind B-DNA, which would explain
the ability of salicylate to relieve repression. Interestingly, the
structure of MarR was solved with two salicylate molecules
bound per monomer, though EmrR, another family member,
appears to bind only one drug molecule per dimer (26). The
“drug” binding pockets are readily accessible, and both use an
arginine to neutralize the negative charge of the bound salicylate. Although salicylate is known to inhibit MarR (27), it
remains unclear if one or both of these binding sites are biologically significant. A ligand-free structure, as well as those of
MarR bound to DNA and bound to other “drugs,” is necessary
to understand fully the action of this repressor.

FIG. 2. The BmrR-TPPⴙ-bmr promoter complex. One subunit is
colored from blue at the N terminus to red at the C terminus, and the
other is colored purple. TPP⫹ is shown as yellow sticks, and glutamates
47, 253, and 266, which surround TPP⫹, are shown as red sticks. Note
the severe distortion of the base pair step that surrounds the bmr
promoter pseudo-dyad (arrow). The bases of this TpA step have slid in
opposite directions, are unpaired, and unstacked from their 5⬘ and 3⬘
neighbors. As a consequence the DNA is bent globally by 50°. This step
is also significantly undertwisted (average helical twist angle is 32°).
The remainder of the bmr promoter returns to a B-DNA-like conformation within 2 bp of the center. The end result of the binding of the
BmrR-drug complex is the remodeling of the promoter such that the
distance between the ⫺10 and ⫺35 boxes and their relative orientation
now more closely resembles those parameters of the ⫺10 and ⫺35
elements of promoters with 17- and 18-bp spacers.
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only ⬃5-fold less well than the full-length BmrR.2
BmrR and MtaN contain a similar winged helix DNA binding
motif, which is contained within the structurally conserved Nterminal four-helix domain. However, a crucial difference between the two proteins is evident in their dimer conformations.
The major groove binding helices (the “recognition” helices) are
separated by 33.3 Å in the MtaN structure but only 30.6 Å in the
DNA- and coactivator-bound form of BmrR, reflecting the shortening of the effective length of the consecutive major grooves of
BmrR-bound bmr promoter. In addition, there is a 15° twist of
the dimer partners, which is mediated through the antiparallel
coiled-coil dimerization interface (36). This twist causes a 7.5 Å
offset in the relative positions of the major groove binding helices.
These differences suggest a mechanism of DNA activation by
MerR family members in which DNA and coactivator binding
cause a shift in the dimer conformation of the protein that leads
to disruption of a centrally located Watson-Crick base pair and
shortening and undertwisting of the DNA (28, 35, 37, 38). The
BmrR-bound DNA structure reveals that the ⫺35 and ⫺10 promoter elements are reconfigured to mimic their spatial locations
in canonical B-form DNA when separated by the typical 17- or
18-bp spacer. This latter conformation must be taken to allow the
productive binding of RNA polymerase and open complex formation. The structure of BmrR bound to the bmr promoter in the
absence of a coactivator is needed to elucidate the full transcription activation mechanism of BmrR. Moreover, whether similar
DNA distortion mechanisms are utilized by other MerR family
members to activate transcription awaits the structure of an
MtaN-mta promoter complex as well as others.

QacR
The Staphylococcus aureus protein QacR is a TetR/CamR family member (39) that represses the qacA multidrug transporter
gene. These plasmid-encoded proteins were named for their ability to confer resistance to quaternary ammonium compounds
(QACs), and recognized compounds include monovalent and bivalent cationic lipophilic antiseptics, antibiotics, and disinfectants (40). Like BmrR, QacR utilizes many of the transporter
substrates (40) in its control of qacA expression. However, QacR
is induced by these compounds rather than activated. QacR binds
a 28-bp pseudopalindromic site (IR1) to repress the transcription

of the qacA mdr gene (40). This length is nearly twice that of
other well characterized DNA binding sites of TetR/CamR family
members. Biochemical and biophysical studies indicated that a
tetramer, rather than a dimer, binds the IR1 site in a cooperative
fashion, i.e. a pair of dimers is assembled on the DNA, as there is
no evidence for QacR tetramers in the absence of DNA, even at
very high concentrations of protein (41).
The unusual mechanism of QacR DNA binding is revealed by
the crystal structure of a QacR-IR1 complex (42). QacR is an all
helical protein, which contains a TetR-like HTH DNA binding
motif embedded within the first three helices (43). Helices
␣4 –␣9 comprise the drug binding and dimerization domains.
Perhaps the most intriguing aspect of QacR-IR1 binding is that
a tetramer does indeed bind as a pair of dimers but without the
dimers contacting each other (Fig. 3a). Rather, cooperativity is
effected by the DNA, the structure of which differs significantly
from canonical B-DNA. The IR1 site is underwound (32.1° twist
per bp and 11.2 bp per turn) and displays a widened major
groove. These features are necessary to allow the QacR recognition helices of each dimer, which display a center-to-center
distance of 37 Å, to bind consecutive major grooves. Thus,
binding of the first QacR dimer and remodeling of the IR1 site
allows the facile binding of the second dimer.
The crystal structures of QacR bound to six different drugs
reveal its multidrug binding and drug induction mechanisms
(44). The most striking finding is the presence of multiple but
overlapping drug binding sites, which is consistent with data on
multidrug transporters (4, 45). The elongated binding site, made
from all C-terminal helices but ␣9, has dimensions of 10 ⫻ 9 ⫻ 23
Å and essentially contains two connected pockets. The R6G and
the Et (ethidium) pockets of the site were named for the drugs
which bind in them (Fig. 3c). The monovalent compounds crystal
violet and malachite green bind in the R6G-Et overlap regions of
the pockets, whereas berberine is located in the R6G pocket. The
long, bivalent drug dequalinium spans the site and fills both the
R6G and Et pockets. Containing an elongated, multifaceted drug
binding site, QacR displays a now obvious yet elegant mechanism
for multiple drug recognition. Interestingly, QacR binds only one
drug molecule per homodimer, unlike TetR, which binds two
tetracycline molecules per dimer (44).
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FIG. 3. Views of the QacR-IR1 and
selected QacR-drug complexes. a, the
QacR dimer of dimers bound to the IR1
site. The protein dimers do not contact
each other but bind cooperatively through
the reconfiguration of the DNA. The subunits of each QacR dimer are shown as
red and blue ribbons, and the DNA is displayed as a white space-filling structure.
b, QacR molecules bound to RG6, Et, and
DNA shown in red, blue, and green, respectively. The backbones were overlaid
from residue 55 to the C terminus and are
displayed as ribbons. Shown in their respective binding sites, the R6G molecule
is displayed as red balls and sticks and
the Et as blue balls and sticks. The backbones of the two drug-bound forms are
nearly identical with an r.m.s. deviation
of 0.66 Å. However, the DNA-bound form
differs significantly as described in the
text. c, close-up view of the drug binding
sites reveals that the two sites are distinct, yet partially overlapping. The “neutralizing” glutamates are shown as pink
balls and sticks (Glu-90-R6G) and cyan
balls and sticks (Glu-120-Et).
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Perspective
We are now at the initial stages of elucidating the structural
underpinnings of multidrug recognition and how these toxic
molecules can regulate bacterial gene expression. Clearly many
major questions remain. For instance, are multidrug binding
pockets limited in their design or have multiple scaffolds
arisen? The QacR and BmrR drug binding pockets share similarities such as the interaction of one or more acidic residues
with their cationic ligands. In an analogous manner MarR uses
an arginine to contact one of its anionic ligands. QacR and
BmrR have multiple aromatic side chains stacking interactions
with their ligands but MarR does not. The multidrug binding
sites of QacR and BmrR are solvent-inaccessible and require a
conformational change for drug access. By contrast, both salicylate binding pockets of MarR are solvent-exposed. Thus, the
answer is still unclear. However, the coordinates of MexR, a
MarR family member, have been deposited in the Protein Data
Bank (46), and its structure should shed some light on the
multidrug binding mechanism of this family. Can bacterial
mdr gene regulators, like their transporter counterparts, bind
more than one drug simultaneously? The structure of the
QacR-dequalinium complex and the 1,100 Å3 volume of the
multidrug binding pocket of QacR suggest such binding is
possible. A similarly large volume is calculated for the drug
binding pocket of PXR, the human nuclear xenobiotic response
regulator (47). Formal proof will require the structure of a
protein-two drug complex. Is there a structural relationship
between the drug binding pockets of the cytosolic mdr gene
regulators and membrane-bound transporters? Although not
an mdr transporter per se, a 4.5-Å resolution crystal structure
of E. coli MsbA, an ABC transporter, has been reported (48).
The structure of this flippase reveals a large positively charged
central cavity, which is the likely ligand binding pocket. Unfortunately, the particulars of the ligand binding site(s) cannot
be described at this resolution, and hence the comparison of the
drug binding pockets of the cytosolic mdr gene regulators and
membrane-bound transporters awaits higher resolution struc-

tural studies on the latter class of proteins. Of note, the coordinates of AcrB, which is a member of the RND family of
multidrug transporters, have been deposited in the Protein
Data Bank. The description of its structure is eagerly awaited.
Over the next few years the structures of other drug-bound mdr
regulators as well as additional studies on BmrR, MarR, and
QacR should address these questions, provide new insight into
multidrug binding, and as importantly delineate novel mechanisms of mdr gene regulation.
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The QacR and BmrR drug binding sites contain a number of
similar features. Both are lined by aromatic residues, which
are found to stack against the ring structures of bound drugs.
Moreover each protein uses buried or partially buried carboxylates to recognize their cationic ligands. In BmrR, Glu-253
appears to be key for the recognition of cationic drugs. By
contrast, QacR contains four partially buried glutamates (residues 57, 58, 90, and 120) that line the extended drug binding
pocket. In the binding of each cationic drug, the positive charge
is neutralized by one or more of these glutamates. The QacR
drug binding site also has several polar residues and solvent
molecules, which interact with the hydrogen bond donors and
acceptors of each drug, likely in a “nondiscriminatory” manner
as each can act as a donor or acceptor.
QacR is induced by each drug, mono- or bivalent, by an identical mechanism. Upon binding drug, helix ␣5 of the drug-bound
subunit undergoes a coil-to-helix transition and expels residues
Tyr-92 and Tyr-93 from the hydrophobic core of the protein. This
coil-to-helix transition extends the ␣5 helix by a turn, which now
impinges upon helix ␣6 moving the latter helix toward the DNA
binding domain. To maintain contacts between ␣6 and ␣1, the
DNA binding domain translates by 9.1 Å and rotates by 36.7°
(Fig. 3b). The change in one subunit is transmitted to the other
(non-drug-bound) subunit through interactions between the ␣6
helices. However, the change in the position of the DNA binding
domain of the drug-free monomer is smaller (3.9-Å translation
and 18.3° rotation). The end result of these drug binding-induced
changes is an increased distance between the recognition helices
from 37 to 48 Å, thus eliminating specific DNA binding.

